CYTOF — Altamira Therapeutics Share Price
0.000.00%
Last trade - 00:00- $0.38m
- $0.74m
- $0.18m
- 40
- 82
- 16
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.06 | ||
| Price to Tang. Book | 0.22 | ||
| Price to Free Cashflow | 0.08 | ||
| Price to Sales | 6.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.1% | ||
| Return on Equity | -10.49% | ||
| Operating Margin | -1159.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.18 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore/ SemaPhore platforms). The Company has over two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. Its delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. AM-401, the drug product is based on its OligoPhore technology.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 18th, 2019
- Public Since
- August 6th, 2014
- No. of Shareholders
- 4
- No. of Employees
- 10
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 3,778,524
- Address
- Clarendon House, 2 Church Street, HAMILTON, 6300
- Web
- https://aurismedical.com/
- Phone
- +41 612011350
- Contact
- Cindy McGee
- Auditors
- BDO AG
Upcoming Events for CYTOF
Full Year 2024 Altamira Therapeutics Ltd Earnings Release
Altamira Therapeutics Ltd Annual Shareholders Meeting
Half Year 2025 Altamira Therapeutics Ltd Earnings Release
Similar to CYTOF
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Altamira Therapeutics share price?
As of Today at 19:13 UTC, shares in Altamira Therapeutics are trading at $0.10. This share price information is delayed by 15 minutes.
How has the Altamira Therapeutics share price performed this year?
Shares in Altamira Therapeutics last closed at $0.10 and the price had moved by -93.76% over the past 365 days. In terms of relative price strength the Altamira Therapeutics share price has underperformed the S&P500 Index by -94.17% over the past year.
What are the analyst and broker recommendations for Altamira Therapeutics?
The overall consensus recommendation for Altamira Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Altamira Therapeutics dividend yield?
Altamira Therapeutics does not currently pay a dividend.
Does Altamira Therapeutics pay a dividend?
Altamira Therapeutics does not currently pay a dividend.
When does Altamira Therapeutics next pay dividends?
Altamira Therapeutics does not currently pay a dividend.
How do I buy Altamira Therapeutics shares?
To buy shares in Altamira Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Altamira Therapeutics?
As of the previous close price of $0.10, shares in Altamira Therapeutics had a market capitalisation of $0.38m.
Where are Altamira Therapeutics shares listed?
Here are the trading details for Altamira Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CYTOF
What kind of share is Altamira Therapeutics?
Based on an overall assessment of its quality, value and momentum Altamira Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Altamira Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Altamira Therapeutics is $5.32. That is 5220.61% above the last closing price of $0.10.
Analysts covering Altamira Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.20 for the next financial year.
Find out moreWhat is the trend in the Altamira Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Altamira Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -79.68%.
As of the last closing price of $0.10, shares in Altamira Therapeutics were trading -79.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Altamira Therapeutics PE Ratio?
The Altamira Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Altamira Therapeutics?
We do not have data on Altamira Therapeutics' directors